Company: DARE
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0001401914-25-000014
Chunk: 36

Company: Dare Bioscience, Inc.
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 36
---
 sufficient comparative data for an executive officer’s position. The Compensation Committee, with the assistance of Aon, reviews a range of market data reference points (generally at the 10 th , 25 th , 50 th and 75 th percentiles of the market data) with respect to target total cash compensation (the sum of base salary and the target annual cash incentive), equity compensation (valued based on an approximation of grant date fair value) and target total direct compensation, and such reference points are considered in making compensation decisions.

When evaluating our executive officer compensation program for 2024, in addition to market data provided by Aon from its global life sciences survey database, the Compensation Committee also reviewed compensation data for executive officers of a peer group of companies, as disclosed in the SEC filings of each of the companies available as of September 2023 (collectively, the "2024 market data"). When developing the proposed list of the peer group companies to be used to assist in making compensation decisions for 2024, the companies selected had a 30-day average market capitalization of between approximately $20.0 million and $260 million, trailing twelve month revenue of less than $80 million, with a majority having less than a $0.5 million, and headcount of between 10 and 116. Following its review of 2024 market data and consistent with Aon’s recommendations, the Compensation Committee determined that the 2024 target total cash compensation (the sum of base salary and target annual cash incentive) of our executive officers should be generally aligned with between the 10 th and 25 th percentile of the 2024 peer group.

| aTyr Pharma Inc.            |     | CytomX Therapeutics |     | Kinnate Biopharma Inc.  |     | Oncternal Therapeutics, Inc. |
| Capricor Therapeutics, Inc. |     | Equillium, Inc.     |     | Kronos Bio              |     | Ovid Therapeutics Inc.       |
| Cardiff Oncology, Inc.      |     | Inmune Bio, Inc.    |     | Leap Therapeutics, Inc. |     | Reneo Pharmaceuticals, Inc.  |
| Corvus Pharmaceuticals      |     | Kezar Life Sciences |     | MediciNova, Inc.        |     | Spruce Biosciences           |

#### Early Decisions Regarding 2025 Compensation
In January 2025, the Compensation Committee, after considering the analysis in materials